Tectonic Therapeutic Q2 net loss widens to $22.3 million; cash at $227.1 million
Tectonic Therapeutic reported second-quarter 2026 results, with a net loss of $22.3 million, up from $20.0 million a year earlier, as research and development and general and administrative expenses rose. Cash and cash equivalents fell to $227.1 million from $236.9 million at March 31, 2026, and the company expects that cash to fund operations into Q1 2029.
Key points
- Net loss of $22.3 million for the three months ended June 30, 2026, versus $20.0 million a year earlier; net loss per share of $1.18 versus $1.07
- R&D expenses rose to $18.0 million from $17.2 million, mainly due to Phase 2 trial costs and stock-based compensation
- Cash and cash equivalents of $227.1 million at June 30, 2026, with cash runway expected into Q1 2029
- TX45 APEX Phase 2 trial completed enrollment in June 2026, with topline results expected in early Q1 2027
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.